Cambridge Cognition Holdings (COGC)

London
111.50
-2.00(-1.76%)
  • Volume:
    16,841
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    114.00 - 114.00

COGC Overview

Prev. Close
113.5
Day's Range
114-114
Revenue
13.72M
Open
113.5
52 wk Range
98.8-189.88
EPS
0.012
Volume
16,841
Market Cap
34.66M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
30,080
P/E Ratio
101.75
Beta
1.13
1-Year Change
-18.01%
Shares Outstanding
31,088,328
Next Earnings Date
25 Jan 2023
What is your sentiment on Cambridge Cognition Holdings?
or
Market is currently closed. Voting is open during market hours.

Cambridge Cognition Holdings News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade
  • Cambridge Cognition climbs on 'strong' H1 results
    • ByProactive Investors-

    Cambridge Cognition Holdings PLC (AIM: COGC) advanced 12% to 120.7p after confirming it followed up a strong performance last year with 44% growth in orders and 31% revenue...

Cambridge Cognition Holdings Company Profile

Cambridge Cognition Holdings Company Profile

Employees
58

Cambridge Cognition Holdings plc is a neuroscience technology company. It is engaged in optimizing the assessment of cognition for better brain health with scientifically validated digital health solutions. Its neuroscience technology solutions demonstrate the value of drug treatments, detect early signs of cognitive impairment for appropriate intervention, and are a major component in the research and understanding of brain health. Its products include CANTAB Recruit, CANTAB Connect, Cognition Kit, Cognition eCOA, CANTAB Connect Research, CANTAB Mobile, CANTAB BrainHealth, CANTAB Insight and NeuroVocalix. Its CANTAB Connect offers digital cognitive assessment solutions for pharmaceutical clinical trials in therapeutic areas. Its Cognition Kit is a custom-designed digital health platform delivering wearable and smartphone applications for high-frequency data collection to demonstrate treatment efficacy and increase the understanding of a disease and a patient's response to medication.

Read More

Analyst Price Target

Average177.00 (+58.74% Upside)
High200
Low154
Price111.5
No. of Analysts2
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellStrong SellNeutral
Technical IndicatorsSellSellStrong SellStrong SellStrong Sell
SummarySellSellStrong SellStrong SellSell
  • So undervalued-buying big
    0